Oral fenretinide slowed the growth of geographic atrophy and reduced the incidence of choroidal neovascularization in patients who were treated over a 2-year period with a daily dose of the drug.
Periocular injections of steroids improve active inflammation and macular edema in most patients with uveitis.
A lubricating eye drop product seems to provide ocular relief for an extended period to patients with mild to moderate dry eye.
A procedure that uses meibomian gland intraductal probing seems to be helpful in patients with severely obstructed meibomian glands.
Patients with moderate to serve dry eye disease are dissatisfied with various dry eye therapies because they do not provide complete symptom relief.
Combination therapy of an anti-platelet-derived growth factor aptamer plus an anti-vascular endothelial lesion regression in 91% of eyes with choroidal neovascularization compared with only 16% of eyes with anti-VEGF monotherapy.
An investigational telescope implant has been given an 8-0 approvable vote by the FDA advisory panel.
An intraoperative wavefront aberrometer seems to be highly beneficial for patients and surgeons because it allows the surgeon to manage astigmatism effectively.
Diabetic macular edema responds to treatment with ranibizumab (Lucentis, Genentech), according to results of the RESOLVE study. The patient responses to the drug in the changes in the visual acuity and central macular thickness were significantly better in the groups treated with two concentrations of ranibizumab compared with the sham-treated group.
A hydrophilic IOL (Afinity CQ2015, STAAR Surgical) seems to be a more efficient delivery system of moxifloxacin 0.5% (Vigamox, Alcon Laboratories) than a hydrophobic IOL (AcrySof SA60, Alcon Laboratories), according to the results of a comparison of lenses soaked in the antibiotic. Both lenses appear to be capable of delivering antibiotics to achieve clinically relevant levels, however.